Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected
about
Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected
description
clinical trial
@en
klinisch onderzoek
@nl
name
Switching From a Regimen of Tw ...... lly-Suppressed, HIV-1 Infected
@en
type
label
Switching From a Regimen of Tw ...... lly-Suppressed, HIV-1 Infected
@en
prefLabel
Switching From a Regimen of Tw ...... lly-Suppressed, HIV-1 Infected
@en
P6153
P1476
A Phase 3b, Multicenter, Open- ...... African American Participants
@en
P1813
BRAAVE 2020
@en
P3098
NCT03631732
P580
2018-08-28T00:00:00Z
P582
2019-08-01T00:00:00Z